$GGBXF Significant Revenue Growth Driven by CBD Retail Expansion
Total first quarter fiscal 2020 revenues increased 77% quarter-over-quarter to $12.7 million
Well-positioned for upcoming holiday season with network of 193 CBD shops
COLUMBUS, OH, Nov. 25, 2019 – Green Growth Brands Inc. (GGB or the Company) (CSE: GGB) (OTCQB: GGBXF) today reported its results for the thirteen-week period ended September 28, 2019. Revenues for the period totaled $12.7M.
“As we approach the holiday shopping season, we are confident in our growth trajectory,” said Peter Horvath, CEO of Green Growth Brands. “We are proud of the topline growth we accomplished in Q1 and are extremely pleased with our current results, which are an indication of future growth. In fact, the four weeks of fiscal November, retail CBD sales were two-thirds of our total CBD sales reported in all of the thirteen weeks of first quarter fiscal 2020, which we are reporting today. This topline growth is reflective of our shift from investing in the foundation of our CBD business to focusing on its execution.
“In a very short-time we have grown a meaningful CBD footprint. We believe our products, network of shops, rapidly growing web business and wholesale relationships position us as a leader in the industry. In the coming quarters we look-forward to reporting similar trends and results for our MSO segment of the business. As we begin to reach scale our consumer and operations expertise will be clearly reflected, not only in the customer experiences we create and the loyalty we drive, but also in our financials as we work towards profitability.”
View Seventh Sense’s holiday campaign and holiday gifting assortment here.
GGB will host a conference call and audio webcast with Chief Executive Officer, Peter Horvath, Chief Operating Officer, Randy Whitaker, and Chief Financial Officer, Brian Logan, at 8:30 AM EST on Tuesday, November 26, 2019.
First Quarter Fiscal 2020 Highlights
- Total revenue for the period was $12.7 million, a sequential increase of 77% over the prior quarter.
- Pro forma revenues for the quarter were $15.3 million, reflecting a full quarter of revenue from The+Source Henderson, which was acquired on August 28, 2019.
- MSO revenues for the quarter were $7.6M, a sequential increase of 38% over the prior quarter, primarily driven by the acquisition of The+Source Henderson.
- The two Nevada-based The+Source dispensaries continue to generate annualized revenue of nearly $15,000 per selling square foot. A best-in-class figure in the cannabis industry and in retail overall.
- CBD revenue for the quarter was $5.1 million, a sequential increase of 201% over the prior quarter. Growth was primarily driven by additional mall-based shop openings, growth in wholesale, and increased overall brand awareness. The Company expects to achieve over $10 million in CBD revenues in second quarter fiscal 2020.
- The Company opened 81 mall-based CBD shops during the quarter, bringing the total number of shops open at quarter’s end to 139 in 34 states. The Company currently operates 193 shops.
- The Company began filling American Eagle Outfitter’s white label order for ‘Mood’ during the quarter. Performance indications are strong, and the Company expects to continue partnering with American Eagle.
__________________________ |
1 eMarketer Retail, “Ecommerce trends and store sales for top retailers” |
First Quarter Fiscal 2020 Financial Statements
The following tables contain financial information for the periods indicated. For full financial information, notes, and management commentary please refer to the MD&A and Financial Statements posted on Green Growth Brands’ Investor Relations site and SEDAR. All financial information is provided in United States dollars, unless otherwise indicated. “Adjusted EBITDA” is equal to net income (loss) before interest, taxes and depreciation and amortization, plus fair value adjustments on sale of inventory and on growth of biological assets, share-based compensation and payments, loss (gain) on equity investments, loss (gain) on foreign exchange, loss (gain) on short-term investments, transaction costs, listing fees and certain one-time non-operating expenses, as determined by management. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash generated by (used for) operations.
Unaudited Condensed Interim Consolidated Statements of Financial Position | ||||||
As at September 28, 2019 and June 30, 2019 | ||||||
(Expressed in United States dollars) | ||||||
September 28, 2019 | June 30, 2019 | |||||
Assets | ||||||
Current Assets | ||||||
Cash and cash equivalents | $ | 6,811,539 | $ | 10,256,008 | ||
Receivables | 2,240,238 | 580,529 | ||||
Prepaid expenses | 3,452,367 | 5,142,618 | ||||
Inventories | 11,282,915 | 10,244,804 | ||||
Biological assets | 1,321,379 | 1,352,097 | ||||
Notes receivable | 48,103 | 47,739 | ||||
Other receivables | 2,969,527 | 3,006,760 | ||||
Deferred lease charges | – | 727,518 | ||||
28,126,068 | 31,358,073 | |||||
Non-current assets | ||||||
Deposits and other assets | 604,414 | 2,880,186 | ||||
Deferred lease charges | – | 2,606,940 | ||||
Notes receivable | 166,724 | 17,999,224 | ||||
Property and equipment, net | 29,052,104 | 18,761,723 | ||||
Right-of-use assets | 69,114,716 | – | ||||
Intangible assets | 101,991,179 | 39,925,984 | ||||
Goodwill | 58,398,385 | 36,253,417 | ||||
Total assets | $ | 287,453,590 | $ | 149,785,547 | ||
Liabilities | ||||||
Current Liabilities | ||||||
Accounts payable and accrued liabilities | 27,370,962 | 16,028,807 | ||||
Taxes payable | 514,535 | 282,593 | ||||
Due to related parties | 8,464,855 | 317,535 | ||||
Notes payable | 34,878,986 | 45,762,540 | ||||
Lease liabilities | 10,512,065 | – | ||||
Embedded derivative liabilities | 618,774 | 1,496,214 | ||||
Convertible debentures | 46,922,616 | 41,623,041 | ||||
129,282,793 | 105,510,730 | |||||
Non-current liabilities | ||||||
Long term accrued liabilities | 1,205,010 | 299,977 | ||||
Lease liabilities | 57,012,239 | – | ||||
Embedded derivative liabilities | 1,188,467 | – | ||||
Convertible debentures | 8,758,271 | – | ||||
Deferred tax liability | 6,985,048 | 1,437,324 | ||||
75,149,035 | 1,737,301 | |||||
Shareholders’ Equity | ||||||
Share capital | 182,371,023 | 119,881,374 | ||||
Reserve for warrants | 16,538,786 | 9,054,624 | ||||
Reserve for share-based compensation | 3,813,158 | 3,147,110 | ||||
Accumulated deficit | (122,566,395) | (92,453,943) | ||||
Accumulated other comprehensive income | 148,286 | 148,286 | ||||
Total equity attributable to shareholders of Green Growth Brands Inc | 80,304,858 | 39,777,451 | ||||
Non-controlling interest | 2,716,904 | 2,760,065 | ||||
Total equity | 83,021,762 | 42,537,516 | ||||
Total liabilities and equity | $ | 287,453,590 | $ | 149,785,547 |
Adjusted EBITDA | |||
(Expressed in United States dollars) | |||
September 28, | September 30, | ||
2019 | 2018 | ||
Net loss after listing fees before income taxes | $ (29,886,676) | $ (2,846,537) | |
Fair value adjustment on sale of inventory | 906,919 | – | |
Fair value adjustment on biological assets | (507,284) | – | |
Stock based compensation | 1,632,922 | – | |
Depreciation and amortization | 3,626,529 | – | |
Pre-opening expenses | 1,547,468 | – | |
Non-operating expenses | 6,264,165 | 156,102 | |
Termination and severance | 421,396 | – | |
Writedown of developed technology | 573,662 | – | |
Other non-operating expenses | 197,204 | – | |
14,662,981 | 156,102 | ||
Adjusted EBITDA | $ (15,223,695) | $ (2,690,435) |
Unaudited Condenseed Interim Consolidated Statements of Loss | |||||
For the 13 weeks ended September 28 2019 and for the three months ended September 30, 2018 | |||||
(Expressed in United States dollars) | |||||
September 28, 2019 |
September 30, 2018 |
||||
Sales | |||||
Revenue | $ | 12,701,958 | $ | – | |
Cost of goods sold | 10,911,000 | – | |||
Gross profit before fair value adjustments | 1,790,958 | – | |||
Fair value change in biological assets included in inventory sold and other charges |
906,919 | – | |||
Unrealized gain on changes in fair value of biological assets |
(507,284) | – | |||
Gross profit | 1,391,323 | – | |||
Operating Expenses | |||||
General and administrative | 9,683,667 | 2,450,960 | |||
Sales and marketing | 10,070,716 | – | |||
Share-based compensation | 1,632,922 | – | |||
Depreciation and amortization | 3,626,529 | – | |||
25,013,834 | 2,450,960 | ||||
(23,622,511) | (2,450,960) | ||||
Other expenses (income) | |||||
Gain in fair value of derivative liabilities | (4,240,710) | – | |||
Interest expense, net | 3,761,477 | 217 | |||
Accretion on convertible debentures | 1,409,583 | – | |||
Foreign exchange (gain) loss | (488,387) | 155,885 | |||
Transaction costs | 5,822,202 | – | |||
Net loss before listing fees and income taxes | (29,886,676) | (2,607,062) | |||
Listing fees | – | 239,475 | |||
Net loss after listing fees | (29,886,676) | (2,846,537) | |||
Income taxes | 356,609 | – | |||
Net loss after income taxes | $ | (30,243,285) | $ | (2,846,537) | |
Less:Non-controlling interest | 43,161 | – | |||
Net Loss attributable to owners of the parent | $ | (30,200,124) | $ | (2,846,537) | |
Net loss per Common Share attributable to the parent | |||||
Basic and Diluted | $ | (0.15) | $ | (0.03) | |
Weighted average common shares | 198,246,478 | 84,428,676 |
Unaudited Condensed Interim Consolidated Statement of Cashflow | ||||||
For the 13 weeks ended September 28, 2019, and for the three months ended September 30, 2018 | ||||||
(Expressed in United States dollars) | ||||||
September 28, 2019 |
September 30, 2018 |
|||||
Cashflow from Operating Activities | ||||||
Net loss after income taxes for the period | $ | (30,243,285) | $ | (2,846,537) | ||
Adjustments for: | ||||||
Stock based compensation | 1,632,922 | – | ||||
Shares and warrants issued for services and fees | 4,115,733 | 567,884 | ||||
Depreciation and amortization | 3,578,965 | – | ||||
Writedown of developed software | 409,022 | – | ||||
Deferred tax expense | (225,333) | – | ||||
Accretion expense | 1,409,583 | – | ||||
Gain in fair value of embedded derivative liabilities | (4,240,710) | – | ||||
Net fair value adjustment on biological assets | 399,635 | – | ||||
Foreign exchange on translation | (488,387) | – | ||||
Changes in working capital balances | ||||||
Receivables | (1,646,660) | – | ||||
Prepaid expenses | 1,690,251 | – | ||||
Other receivables | 1,994,059 | (185,874) | ||||
Inventories | (27,538) | – | ||||
Biological assets | (368,917) | – | ||||
Accounts payable and accrued liabilities | 8,815,006 | (787,634) | ||||
Taxes payable | 231,942 | – | ||||
(12,963,712) | (3,252,161) | |||||
Cashflow from Investing Activities | ||||||
Purchase of property and equipment | (9,723,474) | – | ||||
Purchase of software | (723,738) | – | ||||
Acquisition of business and assets, net of cash acquired | (12,703,263) | – | ||||
Proceeds from sale of equity investment | 11,792 | – | ||||
Advances on acquisitions | – | (32,347,500) | ||||
(23,138,683) | (32,347,500) | |||||
Cashflow from Financing Activities | ||||||
Cash received on warrants exercised | 298,420 | – | ||||
Proceeds from bought deal financing | 36,513,665 | – | ||||
Repayment of notes | (15,485,000) | – | ||||
Principal payments of lease liabilities | (1,589,689) | – | ||||
Proceeds from promissory notes | 12,794,844 | – | ||||
Proceeds from convertible debentures, net of issuance costs | – | 66,061,829 | ||||
32,532,240 | 66,061,829 | |||||
Effect of exchange rates on cash | 125,686 | – | ||||
Increase in cash | (3,444,469) | 30,462,168 | ||||
Cash, beginning of period | 10,256,008 | 4,688,311 | ||||
Cash, end of period | $ | 6,811,539 | $ | 35,150,479 | ||
Supplemental disclosure of cash flow information | ||||||
Interest paid | 445,232 | – | ||||
Income taxes paid | 350,000 | – | ||||
Other non-cash investing and financing activities | ||||||
Change in accrual for construction in progress | 861,479 | – | ||||
Acquisition of business for non-cash | 47,107,913 | – | ||||
Issuance of shares for underwriter fees on bought deal financing | 2,080,494 | – |
Segmented statement of operations for the 14 weeks ended September 28, 2019 and three months ended September 30, 2018 | ||||||||||||||||||||||
(Expressed in United States dollars) | ||||||||||||||||||||||
MSO | CBD | Head office | Allocations | Total | ||||||||||||||||||
2019 | 2018 | 2019 | 2018 | 2019 | 2018 | 2019 | 2018 | 2019 | 2018 | |||||||||||||
Sales | ||||||||||||||||||||||
Revenue | $ | 7,555,102 | $ | – | $ | 5,146,856 | $ | – | $ | – | $ | – | $ | – | $ | – | $ | 12,701,958 | $ | – | ||
Cost of goods sold | 4,575,274 | – | 4,576,384 | – | – | – | 1,759,342 | – | 10,911,000 | – | ||||||||||||
Gross profit before fair value adjustments | 2,979,828 | – | 570,472 | – | – | – | (1,759,342) | – | 1,790,958 | – | ||||||||||||
Fair value change in biological assets included in inventory sold and other charges |
906,919 | – | – | – | – | – | – | – | 906,919 | – | ||||||||||||
Unrealized gain on changes in fair value of biological assets |
(507,284) | – | – | – | – | – | – | – | (507,284) | – | ||||||||||||
Gross profit | 2,580,193 | – | 570,472 | – | – | – | (1,759,342) | – | 1,391,323 | – | ||||||||||||
Operating Expenses | ||||||||||||||||||||||
General and administration | – | – | – | – | 11,433,502 | 2,450,960 | (1,749,835) | – | 9,683,667 | 2,450,960 | ||||||||||||
Sales and marketing | 1,710,707 | – | 8,360,009 | – | – | – | – | – | 10,070,716 | – | ||||||||||||
Stock based compensation | – | – | – | – | 1,632,922 | – | – | – | 1,632,922 | – | ||||||||||||
Depreciation and amortization | 142,564 | – | 2,865,550 | – | 627,922 | – | (9,507) | – | 3,626,529 | – | ||||||||||||
1,853,271 | – | 11,225,559 | – | 13,694,346 | 2,450,960 | (1,759,342) | – | 25,013,834 | 2,450,960 | |||||||||||||
726,922 | – | (10,655,087) | – | (13,694,346) | (2,450,960) | – | – | (23,622,511) | (2,450,960) | |||||||||||||
Non-operating expenses | ||||||||||||||||||||||
Gain in fair value of derivative liabilities | – | – | – | – | (4,240,710) | – | – | – | (4,240,710) | – | ||||||||||||
Interest expense, net | 21,712 | – | 1,117,964 | – | 2,621,801 | 217 | – | – | 3,761,477 | 217 | ||||||||||||
Accretion expense | – | – | – | – | 1,409,583 | – | – | – | 1,409,583 | – | ||||||||||||
Foreign exchange (gain) loss | – | – | – | – | (488,387) | 155,885 | – | – | (488,387) | 155,885 | ||||||||||||
Transaction costs | – | – | – | – | 5,822,202 | – | – | – | 5,822,202 | – | ||||||||||||
Net income (loss) before listing fees and income taxes | 705,210 | – | (11,773,051) | – | (18,818,835) | (2,607,062) | – | – | (29,886,676) | (2,607,062) | ||||||||||||
Listing fees | – | – | – | – | – | 239,475 | – | – | – | 239,475 | ||||||||||||
Net income (loss) after listing fees | 705,210 | – | (11,773,051) | – | (18,818,835) | (2,846,537) | – | – | (29,886,676) | (2,846,537) | ||||||||||||
Income taxes | 356,609 | – | – | – | – | – | – | – | 356,609 | – | ||||||||||||
Net income (loss) after income taxes | $ | 348,601 | $ | – | $ | (11,773,051) | $ | – | $ | (18,818,835) | $ | (2,846,537) | $ | – | $ | – | $ | (30,243,285) | $ | (2,846,537) | ||
Net income (loss) and comprehensive loss attributable to: | ||||||||||||||||||||||
Owners of the parent | 391,762 | – | (11,773,051) | – | (18,818,835) | (2,846,537) | – | – | (30,200,124) | (2,846,537) | ||||||||||||
Non-controlling interest | 43,161 | – | – | – | – | – | – | – | 43,161 | – | ||||||||||||
348,601 | – | (11,773,051) | – | (18,818,835) | (2,846,537) | – | – | (30,243,285) | (2,846,537) | |||||||||||||
Supplemental segemented information | ||||||||||||||||||||||
Assets | 173,818,672 | – | 101,694,365 | – | 11,940,553 | 67,702,122 | – | – | 287,453,590 | 67,702,122 | ||||||||||||
Liabilities | 32,201,594 | – | 79,177,273 | – | 93,052,961 | 66,925,655 | – | – | 204,431,828 | 66,925,655 |
Conference Call Information:
Conference ID: 54236169
Local Toronto Dial-in Number: (+1) 416 764 8609
Local Vancouver Dial-in Number: (+1) 778 383 7417
North American Toll-Free Number: (+1) 888 390 0605
The call and replay archive will be accessible on Green Growth Brands’ Investor Relations website.
About Green Growth Brands Inc.
Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and 8 Fold. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. GGB is expanding its cannabis operations throughout the U.S., via dispensaries in Nevada, Massachusetts and Florida and the largest network of CBD shops in malls across the country and ShopSeventhSense.com. Learn more about the vision at GreenGrowthBrands.com.
Cautionary Statements:
Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018 which is available on the Company’s issuer profile on SEDAR.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including, but not limited to, the Company’s ability to execute on its growth strategy, the Company’s plan to open new dispensaries in the remainder of the calendar year, the Company’s vision to become a multi-state operator with retail stores exceeding certain financial thresholds is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.
The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.
TraderPower Featured Companies
Top Small Cap Market News
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Closes on $8.2M Private Placement
- $CLNN InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
Recent Posts
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
Recent Comments
Archives
- October 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009